Figure 4.

Dysregulation of immune function pathways during risperidone and olanzapine treatment. DE proteins measured in this study are integral parts of several immune function pathways in the KEGG database. The number of proteins altered in RIS- or OLAN-treated mice (relative to VEH-treated controls) in each pathway group were tabulated. The intensity of red (λ = 100–255 nm) reflects the number of proteins per pathway significantly different from VEH-treated mice during RIS treatment (left panel) and OLAN treatment (right panel). Absence of any altered proteins in a particular pathway is depicted in black (λ = 0 nm).